Health & Safety Industry Today

US Generic Injectable Market Size, Share, Trends, Industry Analysis, Report 2024-2032

The US generic injectable market is experiencing significant growth, owing to the demand for affordable medication choices amidst rising healthcare expenses.
Published 30 April 2024

IMARC Group, a leading market research company, has recently releases report titled “US Generic Injectables Market Report by Therapeutic Area (Oncology, Anesthesia, Anti-Infectives, Parenteral Nutrition, Cardiovascular), Container (Vials, Ampoules, Premix, Prefilled Syringes), Distribution Channel (Hospitals, Retail Pharmacy) 2024-2032”. The study provides a detailed analysis of the industry, including the US generic injectables market share, size, trends, and growth forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.

How Big is the US Generic Injectables Market?

The US generic injectables market size reached US$ 19.9 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 44.6 Billion by 2032, exhibiting a growth rate (CAGR) of 9.1% during 2024-2032. 

Request for a PDF sample of this report:

US Generic Injectable Market Trends and Drivers:

The US generic injectable market is experiencing significant growth, owing to the demand for affordable medication choices amidst rising healthcare expenses. Besides this, injectable generics are viewed as a critical component of the solution to lower hospital expenses and increase access to necessary drugs, especially when treating chronic conditions, including diabetes, cancer, and cardiovascular disorders. Moreover, the US generic injectable market is further buoyed by the patent expirations of several blockbuster drugs, which open the door for generic counterparts to enter the market and offer cheaper alternatives. Additionally, the ongoing advancements in production technologies and regulatory approvals expedite the manufacturing and availability of generic injectables, enhancing their adoption across various therapeutic areas.

The strategic initiatives by key market players to expand their product portfolios through partnerships and acquisitions are shaping the US generic injectable market. Furthermore, companies are increasingly investing in research and development (R&D) to introduce high-quality and complex generics, such as peptides and long-acting injectables, that can compete with branded pharmaceuticals on efficacy and safety grounds. Additionally, the COVID-19 pandemic also underscored the critical role of generic injectables in managing public health crises, leading to a heightened focus of government and industry on securing the supply chain and ensuring the uninterrupted availability of these essential drugs. With healthcare providers and patients looking for cost-effective therapies amidst economic uncertainties, the demand for generic injectables is expected to remain strong, driving significant growth in the US generic injectable market.

Leading Companies Operating in the US Generic Injectable Industry:

  • Hospira (Pfizer Inc.)
  • Hikma Pharmaceuticals PLC
  • Fresenius Kabi AG
  • Sagent Pharmaceuticals, Inc
  • Sandoz (Novartis).
  • Henry Shein Inc.

Key Market Segmentation:

The report is organized into distinct sections as follows:

Breakup by Therapeutic Area:

  • Oncology
  • Anesthesia
  • Anti-Infectives
  • Parenteral Nutrition
  • Cardiovascular

Breakup by Container:

  • Vials
  • Ampoules
  • Premix
  • Prefilled Syringes

Breakup by Distribution Channel:

  • Hospitals
  • Retail Pharmacy

Ask Analyst for Customization and Explore Full Report with TOC & List of Figures:

Other Key Points Covered in the Report:

  • COVID-19 Impact
  • Porters Five Forces Analysis
  • Value Chain Analysis
  • Strategic Recommendations

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

Browse More Reports:

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:


134 N 4th St. Brooklyn, NY 11249, USA


Tel No:(D) +91 120 433 0800

United States: +1-631-791-1145 | United Kingdom: +44-753-713-2163

Other Industry News

Ready to start publishing

Sign Up today!